The logo of the Danish pharmaceutical company Novo Nordisk is depicted on February 1, 2017 at their headquarters in Bagsvaerd, outside Copenhagen.

The logo of the Danish pharmaceutical company Novo Nordisk is depicted on February 1, 2017 at their headquarters in Bagsvaerd, outside Copenhagen.
Photo:: Liselotte Sabroe / Scanpix Denmark / AFP: (Getty Images:)

A recent FDA-approved weight loss drug that some researchers have described as a “game changer” sells like hot cakes. On Wednesday, Novo Nordisk announced an unexpectedly strong third quarter, boosted by the launch of the Wegovy obesity drug in the US earlier this summer. The popularity of the drug has made it difficult for some future patients to get it, however, as there is a continuing supply shortage that will probably not go away until early next year.

According to the Associated Press, the Danish pharmaceutical company reports Sales volumes in the third quarter increased by 15% compared to the previous year. The company was aware that Vegovi had played a major role in that growth, as had its sales of type 2 diabetes drugs. “Wegovy’s initial demand in the United States has significantly exceeded our expectations, which underscores the great unmet need of obese people,” said Lars Fruergard Jorgensen, CEO and CEO of Novo Nordrisk, in a statement. announcement: from his earnings.

In clinical trials Wegovy rThe average body weight of obese people in one year was about 15% compared to a placebo. This is the degree of weight loss not seen with older anti-obesity drugs, միայն it is believed that only the most effective (և permanent) bariatric surgeries can achieve greater weight loss. The active ingredient in Wegovy, called semaglutide, is the same as that found in Ozempic և Rybelsus Diabetes. Semaglutide is a synthetic version of GLP-1, a hormone that can help regulate hunger and metabolism. The synthesized version may stay in our system longer than the native GLP-1. Both Vegov and Ozempik are administered by weekly subcutaneous injection or Vegov is used higher dose of semaglutide.

Wegovy’s test results were enough to convince the FDA to approve the drug this June, making it the first new anti-obesity drug in almost a decade. There have been many researchers vocal about their hopes that Vegovi could usher in a new era of obesity medicine. Trials of other GLP-1 և similar hormonal drugs are ongoing, some of which have shown more pronounced weight loss results. At the same time, some researchers and lawyers were fewer excited, insisting that obesity should not be treated as a disease այս, that these drugs may pose unknown long-term risks, including unhealthy cycles of weight loss և. A study by Novo Nordisk found that people who stopped taking Wegovy a few months later tended to regain most of the weight they lost within a year.

The drug is also not free from its side effects, which include gastrointestinal symptoms such as nausea, constipation and diarrhea. In: Clinical trials, about 6.8% of patients stopped taking the drug due to these adverse events. And even some patients in public Supporter: semaglutide was later discontinued due to symptoms they experienced as their dose increased. The drug, like all current GLP-1 drugs, contains a warning about the possible increased risk of rare thyroid cancer, and those with a family history of cancer are clearly not recommended for use.

“My question will be. Does this medicine make people healthier? And I do not think we have the answer. ” Harriet Brown, author և journalist who has written The science of weight loss was told to Gizmodo earlier this year shortly after Wegovy debuted.

One thing is clear: Wegovy’s demand exceeded supply. Novo Nordisk has confessed that it will not be able to follow up, adding that it will probably take until early 2022 for supply to stabilize, that some patients are “about a month or more late to complete prescriptions for Wegovy”. Another problem was the lack of post-mortgage insurance, which can cost up to $ 1,600 a month. Public payers, such as Medicare, will not cover the drug as there is an existing rule on weight loss treatments; only a few private insurers have made it clear that they will reimburse it. In response, the company was providing: A six-month waiver for some insured patients who will limit their out-of-pocket costs to $ 25 a month, or the picture of long-term insurance is still volatile.

Despite some uncertainty about Wegovy, the company is going to do everything. Last month it has started An advertising campaign involving Queen Latifa, allegedly designed as a way to raise awareness about the treatment of obesity, ahead of a more immediate campaign for Vegovi early next year. Novo Nordisk also has was formed Partner with CVS Health to launch a “personalized nutrition training program” for those who have been prescribed obesity treatment at various CVS locations.